ALTURiX Acquires Slow-K® UK Rights

ALTURiX is pleased to announce that it has acquired the UK rights to Slow-K® from Alliance Pharmaceuticals.

Alliance withdrew Slow-K® from the market in late 2014.  ALTURiX have recently acquired the UK rights with the aim of utilising its expertise in slow release technologies to reformulate and relaunch this important product.  

Slow-K® is a potassium chloride extended-release tablet for oral administration, containing 600 mg of potassium chloride (equivalent to 8 mmol) within a wax matrix. 

The specific slow release technology used in Slow-K® is designed to provide a prolonged extended release of potassium from within the matrix to minimise the likelihood of producing high, localised concentrations within the gastrointestinal tract.

Similar technology is also used in Slow Sodium® – a product which is already part of the ALTURiX portfolio.

Once Slow-K® becomes commercially available, it will provide patients with an additional alternative to existing high-dose potassium replacement therapies, and will complement Sando-K® – another product in the ALTURiX portfolio.  Sando-K® is an effervescent high-dose immediate release potassium which has been available to the NHS for over twenty years.

Based in Milton Keynes, the ALTURiX team are constantly liaising with NHS decision-makers to try and better understand current prescribing challenges, with a view to sourcing and delivering prescribing solutions which provide better value and enhanced patient choice.

Please use the Contact Us page if you would like any further information relating to this news item or would like a member of the team to get in touch.

About Sando-K®

Sando-K® is an effervescent tablet containing both potassium chloride and potassium bicarbonate, and is indicated for the prevention and treatment of hypokalaemia.

Hypokalaemia can be caused by potassium depleting drugs such as frusemide, thiazide diuretics, corticosteroids, carbenoxolone and cardiac glycosides.  It can also be commonly caused by severe diarrhoea, vomiting or fistulas; Acid-base disturbances such as alkalosis, renal tubular acidosis and states in which there is aldosterone excess such as Cushing syndrome; Decreased intake of potassium due to malnutrition, alcoholism, and elderly patients with deficient diets.  Since Sando-K® contains chloride, it can also be used to treat hypochloraemic alkalosis.

For complete product information, please see the Summary of Product Characteristics that can be found on www.medicines.org.uk

About Slow Sodium®

Slow Sodium® is a modified release preparation.

Slow Sodium® is a coated, modified release tablet containing high doses of sodium chloride and is indicated for the treatment and prophylaxis of clinically evident sodium chloride deficiency.

For complete product information, please see the Summary of Product Characteristics that can be found on www.medicines.org.uk

To enter the product area of this site you need to confirm you are a Healthcare Professional.

I am a Healthcare Professional

If you are not a Healthcare Professional, please return to the main site.

I am not a Healthcare Professional If you are not a Healthcare Professional and require further information about any of our products, please speak to your doctor, pharmacist or nurse.